FTC Investigates Infant Formula Marketing as Synthetic Opioid Prevalence Rises

Federal regulators are currently investigating the marketing practices of premium infant formula manufacturers, while public health officials track the rising prevalence of synthetic opioids across the country. These developments represent two of the six primary health stories circulating on Thursday, June 18, 2026, as industry experts and government agencies address emerging concerns in consumer safety and substance abuse.

The Federal Trade Commission has initiated a review into the high-end infant formula market to determine if current advertising claims align with nutritional standards and consumer protection laws. Simultaneously, health authorities report an increase in the distribution of synthetic opioids, prompting a renewed focus on overdose prevention and supply chain monitoring. These reports highlight ongoing efforts by oversight bodies to manage risks associated with both the specialized food industry and the illicit drug trade, reflecting a broader trend of increased regulatory scrutiny in public health sectors.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 18, 2026

Author

GOAI